| Zacks Company Profile for GeneLink Inc. (GNLKQ : OTC) |
|
|
| |
| • Company Description |
| GeneLink, Inc., headquartered in Jersey City, New Jersey, through its subsidiaries, operates as a biosciences company that creates genetic tests as the basis for personalized health, beauty, and wellness applications in the United States. Its DNA assessments provide information that enables the customization of nutritional products, skincare products and health maintenance regimens designed to fulfill individual consumer needs. The company has also developed proprietary single nucleotide polymorphism-based genetic profiles, which include GeneLink Nutragenetic Profile and Dermagenetics profiles, which provide a means of predicting an individual's inherent genetic capacity to combat such conditions as oxidative stress and other important selected areas of physiologic health. The Oxidative Stress (OS) profile provides a means of predicting an individual's inherent genetic capacity to combat oxidative stress.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Bernard L. Kasten, Jr., - Chief Executive Officer
Michael Smith - Senior Vice President of Operations
James Monton - Director
Robert P. Ricciardi - Director
Douglas M. Boyle - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 36870F107
SIC: 8071
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
